Abstract
The purpose of this randomized phase III trial was to study whether medroxyprogesterone acetate (MPA) maintenance treatment prolongs the time to progression in advanced breast cancer patients responding to an induction chemotherapy. Patients with progressive advanced breast cancer previously untreated with anthracylines and progestins were given epirubicin (30 mg/m2) and ifosfamide (2 g/m2) on days 1 and 8 at 3‐weekly intervals. Patients without disease progression after 6 cycles of chemotherapy were randomly assigned to receive, until progression, either no treatment or MPA at a daily total dose of 500 mg. Ninety patients were randomized: 46 to the MPA arm and 44 to the observation arm. Median time to progression was longer in the MPA arm: 4.9 months versus 3.7 months in the intent‐to‐treat analysis (p=0.02), and 4.9 months versus 3.0 months in the secondary efficacy analysis (p=0.012). Seven patients were removed from MPA due to side effects. The changes in patient‐rated quality of life scores were similar in both groups. The median length of survival from randomization was 17.4 months for patients receiving MPA and 18.3 months for patients randomized to observation (p=0.39). In conclusion, in patients with advanced breast cancer achieving remission or non‐progression with 6 cycles of epirubicin and ifosfamide chemotherapy, MPA maintenance treatment led to a significant, though modest, prolongation of the time to progression without affecting overall survival of the study patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Veronesi U, Goldhirsch A, Yarnold J: Breast cancer. In: Peckham M, Pinedo H, Veronesi U (eds) Oxford Textbook of Oncology. Oxford University Press, Oxford, 1995, pp 1241–1292
Honig SF: Treatment of metastatic disease. In: Harris JR, Lippman ME, Morrow M, Hellman S (eds) Diseases of the Breast. Lippincott-Raven, Phildelphia, 1996, pp 669–734
Becher R, Kloke O, Hayungs J, Hartwich G, Bartels H, Szanto J, Wolf E, Illiger HJ, Halabi S, Rieche K, Hering KG, Öhl S, DeDycker R, Huhn R, Fischedick AR, Höfeler H, Pielken HJ, Hawig I, Hirche H, Seeber S: Epirubicin and ifosfamide in metastatic breast cancer. Semin Oncol 23 (suppl 7): 28–33, 1996
Coates A, Gebski V, Bishop JF, Jeal PN, Woods RL, Snyder R, Tattersall MHN, Byrne M, Harvey V, Gill G, Simpson J, Drummond R, Browne J, van Cooten R, Forbes JF (for the Australian-New Zealand Breast Cancer Trials Group): Improving the quality of life during chemotherapy for advanced cancer. N Engl J Med 317: 1490–1495, 1987
Harris AL, Cantwell BMJ, Carmichael J, Wilson R, Farndon J, Dawes P, Ghani S, Evans RGB: Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet 335: 186–190, 1990
Muss HB, Case D, Richards F, White DR, Cooper MR, Cruz JM, Powell BL, Spurr CL, Capizzi RL, and the Piedmont Oncology Association: Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N Engl J Med 325: 1342–1348, 1991
Ejlertsen B, Pfeiffer P, Mouridsen HT, Rose C, Overgaard M, Sandberg E, Kristensen B: Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer 29A: 527–531, 1993
Gregory RK, Powles TJ, Chang JC, Ashley S: A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur J Cancer 33: 2194–2197, 1997
Gracia-Giralt E, Ayme Y, Carton M, Daban A, Delozier T, Fargeot P, Fumoleau P, Gorins A, Guerin D, Guerin R, Maillart P, Mauriac L, May-Levin F, Metz R, Namer M, Olivier JP, Commatau E, Pouillart P, Pujade-Lauraine E, Rouesse J, Serrou B, Vitse M, Zylberait D: Second and third line hormonotherapy in advanced post-menopausal breast cancer: A multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen. Breast Cancer Res Treat 24: 139–145, 1992
Gundersen S, Hannisdal E, Lundgren S, Wist E (for the Norwegian Breast Cancer Study Group): Weekly doxorubicin with and without high-dose medroxyprogesterone acetate in hormone-resistant advanced breast cancer: A randomised study. Eur J Cancer 30: 1775–1778, 1994
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207–214, 1981
Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometric 31: 103–115, 1975
Hayward JL, Carbone PP, Heuson JG, Kumaoka S, Segaloff A, Rubens RD: Assessment of response to therapy in advanced breast cancer. Cancer 39: 1289–1294, 1977
George SL, Desu MM: Planning the size and duration of a clinical trial studying the time to some critical event. J Chron Dis 27: 15–24, 1974
O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35: 549–556, 1979
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958
Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719–748, 1959
Cox DR, Oakes D: Analysis of Survival Data. Chapman and Hall, London, 1984
Zelen M: Theory and practice of clinical trials. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR (eds) Cancer Medicine. Lea & Febiger, Philadelphia, 1993, pp 340–360
Robustelli Della Cuna G, Pellegrini A: Medroxyprogesterone acetate in combination with chemotherapy for advanced breast cancer: Updated results and criticisms. In: Pellegrini A, Robustelli Della Cuna G, Pannuti F, Pouillart P, Jonat W (eds) Role of Medoxyprogesterone in Endocrine-related Tumors. Raven Press, New York, 1984, pp 91–104
Hürny C, Bernhard J, Joss R, Willems Y, Cavalli F, Kiser J, Brunner K, Favre S, Alberto P, Glaus A, Senn H, Schatzmann E, Ganz PA, Metzger U (for the Swiss Group for Clinical Cancer Research SAKK, Bern, Switzerland): Feasibility of quality of life assessment in a randomized phase III trial of small cell lung cancer – a lesson from the real world. Ann Oncol 3: 825–831, 1992
Stockler M, Wilcken N, Coates A: Chemotherapy for metastatic breast cancer – when is enough enough? Eur J Cancer 33: 2147–2148, 1997
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kloke, O., Klaassen, U., Oberhoff, C. et al. Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Breast Cancer Res Treat 55, 51–59 (1999). https://doi.org/10.1023/A:1006169012544
Issue Date:
DOI: https://doi.org/10.1023/A:1006169012544